Trending

ALS

BMS joins forces with insitro to develop neurodegenerative treatments

BMS joins forces with insitro to develop neurodegenerative treatments

insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies

X

BMS joins forces with insitro to develop neurodegenerative treatments

https://pharmaphorum.com/news/bms-joins-forces-with-insitro-to-develop-neurodegenerative-treatments/

The ALS patient journey

The ALS patient journey

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ALS is a progressive

X

The ALS patient journey

https://pharmaphorum.com/partner-content/the-als-patient-journey/

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements

X

Mitsubishi Tanabe pulls ALS drug from EMA assessment

https://pharmaphorum.com/news/mitsubishi-tanabe-pulls-als-drug-from-ema-assessment/

AI-discovered candidates show promise in ALS

AI-discovered candidates show promise in ALS

Candidates slow down motor neurone death in patient samples.

X

AI-discovered candidates show promise in ALS

https://pharmaphorum.com/news/ai-candidates-motor-neurone-disease/

FDA approves first ALS treatment for two decades

FDA approves first ALS treatment for two decades

FDA asked Mitsubishi to file Radicava following approval in Japan.

X

FDA approves first ALS treatment for two decades

https://pharmaphorum.com/news/fda/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com